These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37714080)

  • 1. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
    Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
    Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
    Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
    PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers.
    Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Elhendawy MA; Godfrey M; Metwaly AM
    Comput Biol Chem; 2023 Dec; 107():107953. PubMed ID: 37673011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT, Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2 Nicotinamide Analogue.
    Eissa IH; Elkaeed EB; Elkady H; Yousef RG; Alsfouk BA; Elzahabi HSA; Ibrahim IM; Metwaly AM; Husein DZ
    Curr Pharm Des; 2023; 29(36):2902-2920. PubMed ID: 38031271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors:
    Eissa IH; Elkady H; Rashed M; Elwan A; Hagras M; Dahab MA; Taghour MS; Ibrahim IM; Husein DZ; Elkaeed EB; Al-Ghulikah HA; Metwaly AM; Mahdy HA
    Heliyon; 2024 Jan; 10(2):e24005. PubMed ID: 38298627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression.
    Eissa IH; Yousef RG; Sami M; Elkaeed EB; Alsfouk BA; Ibrahim IM; Husein DZ; Elkady H; Metwaly AM
    Pathol Res Pract; 2023 Dec; 252():154924. PubMed ID: 37956639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
    Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
    Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
    Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-
    El-Metwally SA; Elkady H; Hagras M; Husein DZ; Ibrahim IM; Taghour MS; El-Mahdy HA; Ismail A; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    RSC Adv; 2023 Jul; 13(33):23365-23385. PubMed ID: 37545598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
    Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies.
    Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Abd El-Wahab AE; Elkaeed EB; Alsfouk BA; Metwaly AM; Eissa IH
    J Biomol Struct Dyn; 2023; 41(21):11535-11550. PubMed ID: 36617888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
    Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.